Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
b-Zombie_Aqua_Viability_Dye_032713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Save
423101 100 tests ¥19,580
423102 500 tests ¥73,700
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical data sheet

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested
ICFC, ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.
Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  3. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  4. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  7. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  8. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  9. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  10. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  11. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  12. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  13. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  14. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  15. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  16. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  17. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  18. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  19. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  20. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  21. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  22. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  23. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  24. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  25. Miek L, et al. 2022. Immunology. 166:47. PubMed
  26. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  27. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  28. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  29. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  30. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  31. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  32. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  33. Ma T, et al. 2022. Elife. 11: . PubMed
  34. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  35. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  36. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  37. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  38. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  39. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  40. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  41. Balood M, et al. 2022. Nature. 611:405. PubMed
  42. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  43. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  44. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  45. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  46. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  47. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  48. Pleuger C, et al. 2022. Elife. 11: . PubMed
  49. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  50. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  51. Krammer S, et al. 2022. Cells. 12: . PubMed
  52. Chan L, et al. 2022. Cells. 12: . PubMed
  53. Cousin N, et al. 2022. Cells. 12: . PubMed
  54. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  55. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  56. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  57. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  58. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  59. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  60. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  61. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  62. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  63. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  64. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  65. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  66. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  67. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  68. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  69. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  70. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  71. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  72. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  73. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  74. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  75. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  76. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  77. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  78. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  79. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  80. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  81. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  82. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  83. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  84. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  85. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  86. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  87. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  88. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  89. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  90. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  91. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  92. Xu K, et al. 2023. Elife. 12:. PubMed
  93. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  94. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  95. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  96. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  97. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  98. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  99. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  100. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  101. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  102. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  103. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  104. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  105. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  106. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  107. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  108. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  109. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  110. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  111. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  112. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  113. Healy LM, et al. 2020. Glia. 68:811. PubMed
  114. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  115. Wu, W., Ishamuddin, S. H., et al. 2025. Nat Biomed Eng. 9(11),1972-1981. PubMed
  116. Nylund, P., Garrido-Zabala, B., et al. 2025. Blood Adv. 9(19),4825-4841. PubMed
  117. Peng, Y., Li, J., et al. 2025. Diabetes Obes Metab. 27(12),6943-6954. PubMed
  118. Ostermeier, B., Halpern, C., et al. 2025. J Neurovirol. 31(6),507-518. PubMed
  119. D 2025. Clin Transl Immunology. 14(11),e70062. PubMed
  120. He, P., Liu, X., et al. 2025. J Cell Mol Med. 29(21),e70921. PubMed
  121. Moerkens, R., Mooiweer, J., et al. 2025. Stem Cell Reports. 20(12),102715. PubMed
  122. Somanader-Livera, D. V. N., Wei, C., et al. 2025. J Biomed Sci. 32(1),104. PubMed
  123. Perveen, R., Ozaki, I., et al. 2025. Cells. 14(24),0. PubMed
  124. Singh, S. V., Karkempetzaki, A. I., et al. 2025. Cells. 14(24),0. PubMed
  125. Li, W., Liang, L., et al. 2025. Signal Transduct Target Ther. 10(1),420. PubMed
  126. Huang, H., Chai, Y., et al. 2025. Cell Death Dis. 17(1),1. PubMed
  127. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  128. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  129. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  130. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  131. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  132. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  133. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  134. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  135. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  136. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  137. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  138. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  139. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  140. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  141. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  142. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  143. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  144. Price P, et al. 2014. J Virol. 88:10840. PubMed
  145. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  146. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  147. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  148. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  149. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  150. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  151. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  152. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  153. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  154. Toomer G, et al. 2022. Viruses. 14:. PubMed
  155. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  156. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  157. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  158. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  159. Yu X, et al. 2021. Nature. 594:560. PubMed
  160. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  161. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  162. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  163. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  164. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  165. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  166. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  167. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  168. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  169. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  170. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  171. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  172. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  173. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  174. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  175. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  176. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  177. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  178. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  179. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  180. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  181. Munoz MA, et al. 2021. Elife. 10:. PubMed
  182. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  183. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  184. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  185. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  186. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  187. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  188. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  189. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  190. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  191. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  192. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  193. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  194. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  195. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  196. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  197. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  198. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  199. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  200. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  201. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  202. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  203. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  204. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  205. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  206. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  207. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  208. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  209. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  210. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  211. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  212. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  213. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  214. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  215. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  216. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  217. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  218. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  219. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  220. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  221. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  222. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  223. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  224. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  225. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  226. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  227. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  228. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  229. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  230. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  231. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  232. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  233. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  234. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  235. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  236. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  237. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  238. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  239. Romine KA, et al. 2021. Cancer Discov. . PubMed
  240. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  241. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  242. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  243. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  244. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  245. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  246. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  247. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  248. Köchl R, et al. 2020. Elife. 9:00. PubMed
  249. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  250. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  251. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  252. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  253. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  254. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  255. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  256. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  257. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  258. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  259. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  260. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  261. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  262. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  263. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  264. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  265. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  266. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  267. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  268. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  269. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  270. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  271. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  272. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  273. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  274. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  275. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  276. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  277. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  278. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  279. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  280. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  281. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  282. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  283. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  284. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  285. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  286. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  287. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  288. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  289. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  290. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  291. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  292. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  293. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  294. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  295. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  296. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  297. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  298. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  299. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  300. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  301. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  302. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  303. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  304. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  305. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  306. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  307. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  308. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  309. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  310. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  311. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  312. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  313. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  314. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  315. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  316. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  317. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  318. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  319. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  320. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  321. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  322. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  323. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  324. Barington L, et al. 2022. Cells. 11:. PubMed
  325. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  326. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  327. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  328. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  329. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  330. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  331. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  332. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  333. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  334. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  335. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  336. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  337. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  338. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  339. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  340. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  341. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  342. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  343. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  344. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  345. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  346. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  347. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  348. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  349. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  350. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  351. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  352. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  353. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  354. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  355. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  356. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  357. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  358. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  359. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  360. Kumar S, et al. 2022. Gut. . PubMed
  361. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  362. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  363. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  364. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  365. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  366. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  367. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  368. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  369. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  370. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  371. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  372. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  373. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  374. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  375. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  376. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  377. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  378. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  379. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  380. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  381. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  382. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  383. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  384. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  385. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  386. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  387. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  388. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  389. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  390. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  391. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  392. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  393. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  394. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  395. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  396. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  397. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  398. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  399. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  400. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  401. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  402. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  403. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  404. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  405. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  406. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  407. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  408. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  409. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  410. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  411. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  412. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  413. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  414. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  415. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  416. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  417. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  418. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  419. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  420. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  421. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  422. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  423. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  424. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  425. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  426. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  427. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  428. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  429. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  430. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  431. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  432. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  433. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  434. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  435. Yuan C, et al. 2018. iScience. 11:13. PubMed
  436. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  437. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  438. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  439. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  440. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  441. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  442. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  443. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  444. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  445. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  446. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  447. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  448. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  449. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  450. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  451. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  452. Spath S, et al. 2022. iScience. 25:104998. PubMed
  453. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  454. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  455. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  456. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  457. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  458. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  459. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  460. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  461. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  462. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  463. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  464. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  465. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  466. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  467. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  468. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  469. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  470. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  471. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  472. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  473. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 10    Revision Date: 10/16/2025

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account